Research Article

Genotypic and Phenotypic Assessment of Hyaluronidase among Type Strains of a Select Group of Staphylococcal Species

Mark E. Hart, 1, 2 Morgan J. Hart, 3 and Anna J. Roop 3

1 Division of Microbiology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA
2 Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
3 Department of Biology, Ouachita Baptist University, Arkadelphia, AR 71998, USA

Correspondence should be addressed to Mark E. Hart, mark.hart@fda.hhs.gov

Received 13 August 2009; Accepted 15 October 2009

Recommended by William M. Shafer

Hyaluronidases degrade hyaluronic acid, a major polysaccharide of the extracellular matrix of tissues, and are considered important for virulence in a number of Gram-positive and -negative bacteria. The purpose of the present study was to determine the prevalence of hyaluronidase among clinical strains of \textit{Staphylococcus aureus} and among other \textit{Staphylococcus} species. Spent media and chromosomal DNA were assessed for hyaluronidase activity and the absence or presence of a hyaluronidase gene (\textit{hysA}) by Southern analysis, respectively. All \textit{S. aureus} strains examined exhibited at least one hybridizing band (half of the strains exhibited two or more hybridizing bands) when probed for \textit{hysA} and all but three of these strains produced hyaluronidase. In contrast, none of the type strains of 19 other species exhibited either hyaluronidase activity or hybridizing bands when probed for \textit{hysA}. These data support the hypothesis that among members of the \textit{Staphylococcus} genus only strains of \textit{S. aureus} possess the enzyme hyaluronidase. This would suggest that hyaluronidase represents yet another potential virulence factor employed by \textit{S. aureus} to cause disease and may represent a diagnostically important characteristic for distinguishing \textit{S. aureus} from other members of this genus.

Copyright © 2009 Mark E. Hart et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Hyaluronidase, an enzyme that primarily degrades hyaluronic acid, a major component of the extracellular matrix of human tissues, has been found in both Gram-positive and -negative bacteria and, in several cases, has been implicated in the disease process as a means to either invade tissues or generate a source of carbon and energy [1–8]. A role for hyaluronidase in \textit{S. aureus} diseases has been suggested by Makris et al. [9], who demonstrated, using a mouse abscess model, that the number of viable cells recovered for a hyaluronidase mutant strain was significantly less than that for its parent strain. Recent proteomic studies of spent media from \textit{Staphylococcus aureus} UAMS-1 and its regulatory mutants, \textit{sarA}, \textit{agr}, and \textit{sarA agr}, detected two different proteins identified as hyaluronidases [10]. Concentrations of these proteins were higher in the \textit{sarA} and \textit{sarA agr} mutant strains than in the parent and \textit{agr} mutant strains, suggesting the involvement of \textit{SarA}, an important regulator of virulence in \textit{S. aureus}, in the regulation of hyaluronidase [10]. While the exact role of hyaluronidase in \textit{S. aureus} is not known, the involvement of \textit{sarA} in the regulation of the hyaluronidase gene (\textit{hysA}) expression [9, 10] and the identification of genes annotated as putative hyaluronidases in all fourteen sequenced strains of \textit{S. aureus} [11] would indicate that \textit{S. aureus} hyaluronidase is a virulence factor important for some aspect of disease.

The genus \textit{Staphylococcus} is a diverse group of some 41 known species [12, 13]. In the human clinical setting the production of coagulase is usually used to distinguish between \textit{S. aureus} and all other species, which are typically grouped together as the coagulase-negative \textit{staphylococci} (\textit{CoNS}) [14]. However, species other than \textit{S. aureus} produce coagulase even though their encounter in the human clinical
setting is rare [14–18]. These species are *S. intermedius*, *S. delphini*, *S. schleiferi* subsp. *coagulans*, *S. hyicus* subsp. *hyicus*, and *S. lutrae* [13, 19–22].

The presence or absence of hyaluronidase among the staphylococci has been examined, previously. For example, Choudhuri and Chakrabarty [23] examined 523 staphylococcal isolates from human pathologies, and of the 96% that were coagulase positive, only 13% were negative for hyaluronidase activity. Nine of the remaining 21 strains that were coagulase-negative were shown not to produce hyaluronidase [24]. Essers and Radebold [24] examined 368 staphylococcal strains isolated from human specimens, and of the 218 determined to be coagulase negative, only one isolate was hyaluronidase negative. Of the remaining 150 strains determined to be coagulase positive, only one isolate had hyaluronidase activity [24]. An additional 495 strains were examined for their ability to produce DNase and hyaluronidase [24]. Only ten of the 323 DNase positive strains were examined for hyaluronidase activity while 170 of the remaining 172 strains designated DNase negative were also negative for hyaluronidase activity. Collectively, these data [23, 24] indicate that hyaluronidase activity is predominantly seen among strains of staphylococci that exhibit both coagulase and DNase activity, two characteristics typically used to distinguish *S. aureus* from other staphylococcal species, at least in the context of human disease [13].

While it appears that hyaluronidase activity is found among nearly all strains of *S. aureus*, *S. hyicus* subsp. *hyicus*, a strain known to cause infectious exudative epidermitis in swine, has also been reported positive for hyaluronidase activity [13, 19, 25]. To the best of our knowledge, hyaluronidase activity among other species of *Staphylococcus* has not been systematically examined. The purpose of the present study was to determine the prevalence of hyaluronidase in members of the genus *Staphylococcus*, primarily those associated with human disease.

### 2. Materials and Methods

#### 2.1. Staphylococcal Strains and Growth Conditions

*S. aureus* strains used in this study are listed in Table 1. While these strains were obtained primarily from two sources, the University of Arkansas for Medical Sciences and the University of Nebraska Medical Center, the strains represent a diverse group of clinical isolates originally obtained from different geographical locations, outbreaks, and disease syndromes. Other species examined were *S. auricularis* ATCC 35753T, *S. capitis* subsp. *capitis* ATCC 27840T, *S. caprae* ATCC 35538T, *S. carnosus* subsp. *carnosus* ATCC 51365T, *S. chromogenes* ATCC 43764T, *S. cohnii* subsp. *cohnii* ATCC 29974T, *S. delphini* ATCC 49171T, *S. epidermidis* ATCC 14990T, *S. epidermidis* ATCC 12228, *S. haemolyticus* ATCC 29970T, *S. hominis* subsp. *hominis* ATCC 27844T, *S. hyicus* subsp. *hyicus* ATCC 11249T, *S. intermedius* ATCC 29663T, *S. lugdunensis* ATCC 43080T, *S. saprophyticus* ATCC 19701T, *S. schleiferi* subsp. *coagulans* ATCC 49549T, *S. schleiferi* subsp. *schleiferi* ATCC 43808T, *S. sciuri* subsp. *sciuri* ATCC 29062T, *S. simulans* ATCC 27848T, *S. warneri* ATCC 27836T, and *S. xylosus* ATCC 29971T. Strains were maintained as frozen (–80°C) stocks in brain heart infusion broth (BHI; Difco Laboratories, Detroit, Mich.) containing 25% (w/v) glycerol and routinely streaked for isolation on tryptic soy broth (TSB; Difco) containing agar (1.5%). Flasks containing 20 mL of TSB were inoculated from plate cultures and incubated at 37°C overnight (15–18 hours) with rotary (180 rpm) aeration.

2.2. DNA Isolation and Southern Analysis. Chromosomal DNA was isolated using the GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich Chemical Co., St. Louis, Mo) and digested with *ClaI* restriction endonuclease, resolved by agarose gel electrophoresis, and transferred to neutral nylon membranes (MagnaGraph; Micron Separations Inc., Westborough, Mass.) by passive diffusion. Membranes were hybridized overnight with a digoxigenin-labeled (Roche Molecular Biochemicals, Indianapolis, Ind.) amplicon generated by PCR using either *S. aureus* UAMS-1 or RN6390 (8325 lineage) chromosomal DNA as template and primers 

#### 2.3. Concentration of Spent Media. Optical density readings of overnight cultures (15–18 hours) were determined spectrophotometrically at 550 nm and used to dilute each culture with TSB to an optical density of 3.0 in a total volume of 10 mL. Diluted cultures were centrifuged (10,000 ×g, for 10 minutes at 4°C) and spent media were filter sterilized before concentration using ultrafiltration (Centricon Ultrapel YM-3 filters with 3,000 MWCO, Millipore Corporation, Bedford, Maine) and a one-hour centrifugation (7,500 ×g) at 4°C. The retentates were recovered and stored at −80°C until needed.

2.4. Plate Assay for Detecting Hyaluronidase in Spent Media. Sterile plastic square plates containing 1% (w/v) SeaKem LE agarose (Cambrex BioScience Rockland, Inc., Rockland, Maine), 1% (w/v) bovine serum albumin (BSA; Fraction V; Fisher Scientific, Fair Lawn, NJ), and 0.4 mg mL⁻¹ of hyaluronic acid (HA; Sigma, H-1504; potassium salt, from human umbilical cord) in 0.3 M sodium phosphate buffer (pH 5.3) were prepared according to Steiner and Cruce [27]. Once the agarose containing BSA and HA had solidified, 4 mm wells were made aseptically, and 20 μL of spent media was pipetted into each well. Plates were incubated overnight (15–18 hours) at 37°C prior to flooding each plate with 2 M acetic acid. Clear zones were visualized against...
| Strain     | Relevant description | Source                      | HA activity* | hysA† |
|------------|----------------------|-----------------------------|--------------|-------|
| NCH 265   | ATCC 29213           | ATCC§                       | 13.2 ± 1.3   | 1     |
| NCH 340   | ATCC 12600†          | ATCC                        | 9.7 ± 0.6    | 1     |
| NTH 125   | ATCC 23923           | ATCC                        | 8.7 ± 0.8    | 2     |
| NCH 49    | MN8 (vaginal TSS†)   | NARSA†                      | 8.7 ± 0.3    | 2     |
| NCH 47    | Mu50 (HA-MRSA)       | NARSA                       | 9.2 ± 0.3    | 1     |
| NTH 51    | MW2 (CA-MRSA)        | NARSA                       | 9.5 ± 0.5    | 1     |
| NCH 48    | N315 (HA-MRSA)       | NARSA                       | 7.0 ± 0.5    | 1     |
| NCH 328   | Newman               | T. Foster, Trinity College, Dublin, Ireland | 5.8 ± 2.5 | 1 |
| NCH 331   | Newman (sigB)        | T. Foster, Trinity College, Dublin, Ireland | 10.0 ± 0 | 1 |
| NCH 88    | Sanger-252 (EMRSA-16)| NARSA                       | 7.2 ± 2.0    | 2     |
| NCH 78    | SH1000 (RN6390, rsb+) | S. Foster, Univ. Sheffield, Sheffield, England | 11.3 ± 0.6 | 1 |
| NCH 79    | SH1000 (RN6390, rsb) | S. Foster, Univ. Sheffield, Sheffield, England | 12.5 ± 3.0 | 1 |
| NTH 13    | UAMS-1               | M.S. Smeltzer, UAMS†        | 9.0 ± 1.3    | 2     |
| NCH 310   | USA300 (Miss.)       | M.S. Smeltzer, UAMS        | 9.8 ± 0.3    | 1     |
| NCH 338   | USA300 (LAC)         | A.R. Horswill, University of Iowa | 10.2 ± 1.6 | 1 |
| NCH 239   | Vaginal TSS          | P.D. Fey, UNMC†             | 6.8 ± 0.6    | 2     |
| NCH 240   | Vaginal TSS          | P.D. Fey, UNMC              | 8.8 ± 1.8    | 1     |
| NCH 241   | Vaginal TSS          | P.D. Fey, UNMC              | 0 ± 0        | 2     |
| NCH 242   | Vaginal TSS          | P.D. Fey, UNMC              | 0 ± 0        | 1     |
| NCH 243   | Vaginal TSS          | P.D. Fey, UNMC              | 8.5 ± 0.7    | 2     |
| NCH 244   | Vaginal TSS          | P.D. Fey, UNMC              | 10.0 ± 0.5   | 1     |
| NCH 245   | Vaginal TSS          | P.D. Fey, UNMC              | 9.7 ± 0.6    | 2     |
| NCH 246   | Vaginal TSS          | P.D. Fey, UNMC              | 7.8 ± 0.8    | 2     |
| NCH 247   | Vaginal TSS          | P.D. Fey, UNMC              | 6.7 ± 1.2    | 1     |
| NCH 248   | Vaginal TSS          | P.D. Fey, UNMC              | 8.0 ± 1.7    | 2     |
| NCH 249   | Vaginal TSS          | P.D. Fey, UNMC              | 8.0 ± 0.9    | 2     |
| NCH 250   | Vaginal TSS          | P.D. Fey, UNMC              | 0 ± 0        | 2     |
| NCH 251   | Vaginal TSS          | P.D. Fey, UNMC              | 8.3 ± 1.0    | 2     |
| NCH 252   | Vaginal TSS          | P.D. Fey, UNMC              | 7.3 ± 0.8    | 2     |
| NCH 253   | Vaginal TSS          | P.D. Fey, UNMC              | 6.8 ± 1.0    | 2     |
| NCH 254   | Vaginal TSS          | P.D. Fey, UNMC              | 8.2 ± 0.8    | 2     |
| NTH 68    | UAMS-625 (Abscess)   | M.S. Smeltzer, UAMS         | 11.0 ± 3.0   | 1     |
| NTH 69    | UAMS-632 (Wound)     | M.S. Smeltzer, UAMS         | 6.2 ± 1.0    | 2     |
| NTH 70    | UAMS-635 (Blood)     | M.S. Smeltzer, UAMS         | 13.5 ± 1.3   | 1     |
| NTH 71    | UAMS-636 (Wound)     | M.S. Smeltzer, UAMS         | 13.0 ± 0     | 1     |
| NTH 72    | UAMS-639 (Tracheal)  | M.S. Smeltzer, UAMS         | 8.7 ± 0.8    | 2     |
| NTH 73    | UAMS-640 (Abscess)   | M.S. Smeltzer, UAMS         | 10.3 ± 0.6   | 2     |
| NTH 74    | UAMS-641 (Blood)     | M.S. Smeltzer, UAMS         | 7.2 ± 1.0    | 2     |
| NTH 75    | UAMS-655 (Blood)     | M.S. Smeltzer, UAMS         | 13.2 ± 0.8   | 2     |
| NTH 76    | UAMS-682 (Outbreak 2)| M.S. Smeltzer, UAMS         | 12.0 ± 1.0   | 2     |
| NTH 77    | UAMS-687             | M.S. Smeltzer, UAMS         | 9.0 ± 0.5    | 1     |
| NTH 78    | UAMS-688             | M.S. Smeltzer, UAMS         | 11.8 ± 0.8   | 2     |
| NTH 79    | UAMS-689             | M.S. Smeltzer, UAMS         | 10.8 ± 0.8   | 3     |
| NTH 80    | UAMS-690 (Outbreak 1)| M.S. Smeltzer, UAMS         | 0.5 ± 0.6    | 1     |
| NTH 81    | UAMS-691 (Outbreak 2)| M.S. Smeltzer, UAMS         | 12.8 ± 1.0   | 3     |
| NTH 82    | UAMS-697             | M.S. Smeltzer, UAMS         | 14.0 ± 0.5   | 1     |

*Values represent the mean diameter in millimeters ± the standard deviation of three independent determinations.
†Values represent the number of chemiluminescent bands detected when hybridized with a hysA specific probe.
§American Type Culture Collection (ATCC), Manassas, Va.
†Type strain
†Toxic shock syndrome.
††Network for Antimicrobial Resistant Staphylococcus aureus.
†‡University of Arkansas for Medical Sciences, Little Rock, Ark.
†§University of Nebraska Medical Center, Omaha, Neb.
Figure 1: Southern analysis of chromosomal DNA from Staphylococcus species hybridized with a probe specific for hysA. Panel (a) S. aureus NCH 239 (1), NCH 240 (2), NCH 241 (3), NCH 242 (4), NCH 243 (5), NCH 244 (6), NCH 245 (7), NCH 246 (8), S. auricularis ATCC 33753T (9), S. capitis subsp. capitis ATCC 27840T (10), S. caprae ATCC 35538T (11), S. carnosus subsp. carnosus ATCC 51365T (12), S. chromogenes ATCC 43764T (13), S. cohnii subsp. cohnii ATCC 29974T (14), S. delphini ATCC 49171T (15), S. hominis subsp. hominis ATCC 27844T (16), S. aureus NCH 78 (17), and NCH 88 (18). Panel (b) S. aureus NTH 74 (1), NTH 75 (2), NTH 76 (3), NTH 77 (4), NTH 78 (5), NTH 79 (6), NTH 80 (7), NTH 81 (8), S. intermedius ATCC 29663T (9), S. lugdunensis ATCC 43809T (10), S. saprophyticus ATCC 19701T (11), S. schleiferi subsp. schleiferi ATCC 43808T (12), S. epidermidis ATCC 12228 (13), S. aureus NTH 125 (14), NCH 265 (15), S. intermedius ATCC 29633T (16), NCH 78 (17), and NCH 88 (18). Panel (c) S. aureus NCH 47 (1), NCH 48 (2), NCH 49 (3), NCH 51 (4), S. sciuri subsp. sciuri ATCC 29062T (5), S. simulans ATCC 27848T (6), S. warneri ATCC 27836T (7), S. xylosus ATCC 29971T (8), S. aureus NTH 13 (9), NCH 78 (10), NCH 79 (11), NTH 82 (12), NCH 88 (13), S. haemolyticus ATCC 29970T (14), NCH 328 (15), NCH 331 (16), NCH 78 (17), and NCH 88 (18). M: marker (kilobases).

Figure 2: Southern analysis of chromosomal DNA from Staphylococcus species hybridized with a probe specific for hysA. Panel (a) S. aureus NCH 247 (1), NCH 248 (2), NCH 249 (3), NCH 250 (4), NCH 251 (5), NCH 252 (6), NCH 253 (7), NCH 254 (8), NCH 78 (9), and NCH 88 (10). Panel (b) S. aureus NCH 310 (1), NCH 338 (2), NCH 340 (3), S. epidermidis ATCC 14990T (4), S. aureus NTH 68 (5), NTH 69 (6), NTH 70 (7), NTH 71 (8), NTH 72 (9), NTH 73 (10), NCH 78 (11), and NCH 88 (12). M: marker (kilobases).

2.5. Plate Assay for Detecting Hyaluronidase-Producing Colonies in Mixed Culture. Tryptic soy broth (6 g in 120 mL of water) containing 1% (w/v) agarose was sterilized by autoclaving. The molten medium was equilibrated to 50°C prior to the addition of 40 mL of filter-sterilized BSA (5% [w/v] prepared in water) and 40 mL of filter-sterilized HA (1 mg mL⁻¹ prepared in water) both equilibrated to 50°C. The suspension was mixed and dispensed as 20 mL portions into each of ten Petri plates (15 × 100 mm). The medium (TSHA) was allowed to solidify and plates were incubated overnight at 37°C before use. Overnight cultures of S. aureus strains ATCC 33753 and Newman and S. epidermidis strain ATCC 12228 were diluted with TSB, mixed in equal portions, and plated onto TSHA plates to yield 30-300 colonies per plate. Plates were incubated overnight (15–18 hours) at 37°C prior to flooding each plate with 2 M acetic acid to precipitate undigested HA conjugated to BSA.

3. Results

3.1. Hyaluronidase Activity of S. Aureus. Hyaluronidase activity was detected for 93% (40 of 43) of S. aureus strains (Table 1) examined while none of the remaining species exhibited hyaluronidase activity (data not shown) including S. hyicus subsp. hyicus ATCC 11249T (Figure 3(a)); the only species other than S. aureus reported to have hyaluronidase activity [13, 19, 25].
The hyaluronidase-producing strains of *S. aureus* examined included three ATCC strains, eight sequenced strains, and two isolates of pulse-field type, USA-300 (Miss and LAC) (Table 1). The remaining strains examined included 17 vaginal toxic shock syndrome- (TSS-) producing clinical isolates and 15 clinical strains (Table 1). The identity of the three hyaluronidase nonproducing strains as *S. aureus* (NCH 241, 242, and 250) was determined by Gram stain, growth on mannitol salt agar and catalase, coagulase, and DNase activities (data not shown). Their identities were confirmed using the Vitek 2 Compact (bioMérieux, Durham, N.C.) automated system and the ID-GP identification cards (bioMérieux). Strain NCH 242 was identified as *S. aureus* with low discrimination between it and *S. intermedius* but was positive with the Voges-Proskauer test. *Staphylococcus intermedius*, like *S. aureus*, produces coagulase and DNase as well as utilize mannitol [13]. However, unlike *S. aureus*, *S. intermedius* is unable to ferment glucose to acetylmethylcarbinol (acetoin), and thus, is negative with the Voges-Proskauer test [13].

3.2. Southern Analysis. Chromosomal DNA was isolated from all strains and digested with the restriction endonuclease, *ClaI*. This enzyme was chosen because it does not cut within the open reading frame of any of the hyaluronidase genes found in the 14 sequenced *S. aureus* genomic databases (data not shown). Digested DNA resolved by gel electrophoresis was analyzed by Southern analysis using a probe generated from the sequence of one of the hyaluronidase genes (*hysA1*) found in *S. aureus* UAMS-1 and from the corresponding gene found in *S. aureus* RN6390. Under high stringency conditions (65°C and low salt) both probes hybridized to the same *ClaI* fragment containing a hyaluronidase gene with equal intensities (data not shown). *Staphylococcus aureus* SH1000 (8325 lineage) and Sanger-252 were included in all Southern analysis as representative strains containing one and two *hysA* genes, respectively, as demonstrated by sequence analysis of their respective databases and independent cloning and sequencing of all three genes (data not shown).

Approximately half (53.5%) of the 43 *S. aureus* strains examined exhibited two hybridizing bands and two strains (NTH 79 and 81) exhibited three hybridizing bands (Table 1 and Figures 1 and 2). These data suggest that these strains contain multiple copies of the hyaluronidase gene. The existence of smaller *ClaI* hybridizing fragments was noted for two strains, NTH 75 and NTH 78, and so the potential for restriction fragment length polymorphism exists. None of the remaining 19 species of *Staphylococcus* exhibited a hybridizing band for *hysA* (Figures 1 and 2) including the type strain for *S. hyicus* subsp. *hyicus* ATCC 11249T (Figure 3(b)).

3.3. Detecting Hyaluronidase-Producing Strains on TSHA. Three strains of *Staphylococcus*, *S. aureus* strain ATCC 33753, *S. aureus* strain Newman, and *S. epidermidis* strain ATCC 12228 exhibiting a large (13.2 ± 1.3), small (5.8 ± 2.5), and no zone of activity on HA plates, respectively, were mixed and plated onto TSHA to determine whether or not TSHA could be used to discern *Staphylococcus* strains expressing hyaluronidase at different levels. All three strains could easily be discerned, as evident by the differences in zone sizes after overnight incubation at 37°C (Figure 4).

4. Discussion

Previous studies [23, 24] examined a large number of staphylococcal strains for the presence of hyaluronidase activity. While species identity was not determined in most cases, the strains were characterized as either positive or negative for coagulase or DNase activities, characteristics typically used to distinguish *S. aureus* from other staphylococcal species [13]. In these studies [23, 24] the vast majority (93%) of strains that exhibited coagulase and DNase activities also exhibited hyaluronidase activity.
In the present study, we have examined the type strain for 20 different species of *Staphylococcus* for their ability to degrade hyaluronic acid and of these, only *S. aureus* strains exhibited hyaluronidase activity. In addition, over half of the *S. aureus* strains examined exhibited two or more genes for hyaluronidase. While the number of genes per strain will need to be confirmed, we know from the genomic databases of *S. aureus* Sanger-252 and RF-122 [11, 28, 29] and the proteomic analysis of *S. aureus* UAMS-1 [10] that these strains contain two genes for hyaluronidase. Whether or not the presence of two or more hyaluronidase genes affords some metabolic or pathogenic advantage is currently under investigation. However, it must be pointed out that an increase in the number of potential genes for any one strain did not necessarily result in an increase in hyaluronidase activity as determined with the hyaluronidase assay used in this study. In addition, not all *S. aureus* strains produced hyaluronidase although Southern analysis indicated the presence of at least one gene in each of the three strains that failed to exhibit hyaluronidase activity. It is also interesting that two of these hyaluronidase nonproducing strains appear to have two *hysA* genes. While at present we have no supporting data, this might suggest that either these strains carry two copies of the same defective gene or an important regulator of *hysA* expression is nonfunctional. Nevertheless, given the limited number of *S. aureus* strains examined in our study and the fact that some strains did not produce hyaluronidase would suggest that the lack of hyaluronidase by *S. aureus* is more prevalent than originally thought and that the enzyme may not be a contributing factor in virulence. Whether this is true or not will require further investigation particularly given that hyaluronidase has been implicated as a virulence factor in the mouse abscess model [9] and that the primarily virulence gene regulator, SarA, controls its expression [9, 10].

We are also intrigued that under our assay conditions as well as the Southern analysis that *S. hyicus* subsp. *hyicus*, a strain known to cause infectious exudative epidermitis in swine and reported to have hyaluronidase activity [13, 19, 25], exhibited no activity nor did it have a hybridizing band corresponding to the *hysA* gene from *S. aureus*. Currently, it is unclear as to why this discrepancy exists other than previous investigations [13, 19, 25] relied on the appearance of nonmucoid colonies of *Streptococcus equi*, which possesses a hyaluronic acid-containing capsule [30, 31] on blood agar when *Streptococcus equi* was plated as a lawn and *Staphylococcus* species, including *S. hyicus* were “spot” inoculated.
onto the lawn [32]. This would suggest, perhaps, that some factor other than hyaluronidase contributes to the formation of nonmucoid *Streptococcus equi* colonies.

Lastly, while the method employed in this study clearly distinguished hyaluronidase-producing colonies from those that did not, more than likely the detection of hyaluronidase activity as a diagnostic test for the presumptive identification of *S. aureus* would not be feasible given the fact that not all *S. aureus* strains possess hyaluronidase activity. However, using methods that detect the presence or absence of the gene could possibly be used as 100% of the *S. aureus* strains examined in this study contained at least one gene for *lysA*.

**Acknowledgments**

This research was supported by protocol E0717501 awarded to M. E. Hart by the National Center for Toxicological Research (NCTR) of the United States Food and Drug Administration. Support for undergraduates M. J. Hart and A. J. Roop was provided by the Student Research Participation Program at NCTR and administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration and by the Division of Microbiology at NCTR. M. J. Hart and A. J. Roop contributed equally to this work. The authors are grateful to Don Paine and Roger Steele for identification of strains. They are also indebted to Drs. Carl Cerniglia, Chris Elkins, and John Sutherland for careful evaluation of the manuscript. The views presented in this article do not necessarily reflect those of the United States Food and Drug Administration.

**References**

[1] Q. Cheng, M. C. Yu, A. R. Reeves, and A. A. Salyers, “Identification and characterization of a *Bacillus* gene, *cfsA*, which encodes an outer membrane protein that is essential for growth on chondroitin sulfate,” *Journal of Bacteriology*, vol. 177, no. 13, pp. 3721–3727, 1995.

[2] K. Homer, H. Shain, and D. Beighton, “The role of hyaluronidase in growth of *Streptococcus intermedius* on hyaluronic,” *Advances in Experimental Medicine and Biology*, vol. 418, pp. 681–683, 1997.

[3] W. L. Hynes and S. L. Walton, “Hyaluronidases of gram-positive bacteria,” *FEMS Microbiological Letters*, vol. 183, no. 2, pp. 201–207, 2000.

[4] J. I. Rood and S. T. Cole, “Molecular genetics and pathogenesis of *Clostridium perfringens*,” *Microbiological Reviews*, vol. 55, no. 4, pp. 621–648, 1991.

[5] H. Shain, K. A. Homer, and D. Beighton, “Degradation and utilisation of chondroitin sulphate by *Streptococcus intermedius*,” *Journal of Medical Microbiology*, vol. 44, no. 5, pp. 372–380, 1996.

[6] L. D. Smith, “Virulence factors of *Clostridium perfringens*,” *Reviews of Infectious Diseases*, vol. 1, no. 2, pp. 254–262, 1979.

[7] C. R. Starr and N. C. Engleberg, “Role of hyaluronidase in subcutaneous spread and growth of group A *Streptococcus*,” *Infection and Immunity*, vol. 74, no. 1, pp. 40–48, 2006.

[8] R. Stern and M. J. Jedrzejas, “Hyaluronidases: their genomics, structures, and mechanisms of action,” *Chemical Reviews*, vol. 106, no. 3, pp. 818–839, 2006.

[9] G. Makris, J. D. Wright, E. Ingham, and K. T. Holland, “The hyaluronate lyase of *Staphylococcus aureus*: a virulence factor?” *Microbiology*, vol. 150, no. 6, pp. 2005–2013, 2004.

[10] R. C. Jones, J. Deck, R. D. Edmondson, and M. E. Hart, “Relative quantitative comparisons of the extracellular protein profiles of *Staphylococcus aureus* UAMS-1 and its sarA, agr, and sarA agr regulatory mutants using one-dimensional polyacrylamide gel electrophoresis and nanocapillary liquid chromatography coupled with tandem mass spectrometry,” *Journal of Bacteriology*, vol. 190, no. 15, pp. 5265–5278, 2008.

[11] P. Kersey, L. Bower, L. Morris, et al., “Integr8 and genome reviews: integrated views of complete genomes and proteomes,” *Nucleic Acids Research*, vol. 33, pp. D297–D302, 2005.

[12] J. P. Euzéby, “List of bacterial names with standing in nomenclature: a folder available on the Internet,” *International Journal of Systematic Bacteriology*, vol. 47, no. 2, pp. 590–592, 1997.

[13] W. E. Kloos and K. H. Schleifer, “*Staphylococcus*,” in *Bergey’s Manual of Systematic Bacteriology*, P. H. A. Sneath, N. S. Mair, M. E. Sharpe, and J. G. Holt, Eds., pp. 1013–1035, The Williams and Wilkins, Baltimore, Md, USA, 1986.

[14] G. L. Archer, “*Staphylococcus epidermidis* and other coagulase-negative staphylococci,” in *Principles and Practice of Infectious Diseases*, G. L. Mandell, J. E. Bennett, and R. Dolin, Eds., pp. 1777–1784, Churchill Livingstone, New York, NY, USA, 1995.

[15] D. J. Diekema, M. A. Pfaffer, F. J. Schnitz, et al., “Survey of infections due to *Staphylococcus* species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997–1999,” *Clinical Infectious Diseases*, vol. 32, no. 10, supplement 2, pp. S114–S132, 2001.

[16] J. Huebner and D. A. Goldmann, “Coagulase-negative staphylococci: role as pathogens,” *Annual Review of Medicine*, vol. 50, pp. 223–236, 1999.

[17] W. E. Kloos and T. L. Bannerman, “Update on clinical significance of coagulase-negative staphylococci,” *Clinical Microbiology Reviews*, vol. 7, no. 1, pp. 117–140, 1994.

[18] W. E. Kloos and T. L. Bannerman, “*Staphylococcus* and *Micrococcus*,” in *Manual of Clinical Microbiology*, P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken, Eds., pp. 289–298, ASM Press, Washington, DC, USA, 1995.

[19] L. A. Devriese, V. Héjek, P. Oeding, et al., “*Staphylococcus hyicus* (Sompolinsky 1953) comb. nov. and *Staphylococcus hyicus* subsp. *chromogenes* subsp. nov.,” *International Journal of Systematic Bacteriology*, vol. 47, no. 3, pp. 724–726, 1997.

[20] M. M. Martín de Nicolás, A. Vindel, and J. A. Sáez-Nieto, “Epidemiological typing of clinically significant strains of coagulase-negative staphylococci,” *Journal of Hospital Infection*, vol. 29, no. 1, pp. 35–43, 1995.

[21] M. A. Pfaller, F. J. Schnitz, and S. A. Neu, “*Staphylococcus epidermidis* and other coagulase-positive species isolated from otters,” *International Journal of Systematic Bacteriology*, vol. 47, no. 3, pp. 724–726, 1997.

[22] P. E. Varaldo, R. Kilpper-Bálz, F. Biavasco, G. Satta, and K. H. Schleifer, “*Staphylococcus delphini* sp. nov., a coagulase-positive species isolated from dolphins,” *International Journal of Systematic Bacteriology*, vol. 38, no. 4, pp. 436–438, 1988.

[23] K. K. Choudhuri and A. N. Chakrabarty, “Hyaluronate lyase activity of staphylococci,” *Indian Journal of Experimental Biology*, vol. 7, no. 3, pp. 183–185, 1969.
[24] L. Essers and K. Radebold, “Rapid and reliable identification of Staphylococcus aureus by a latex agglutination test,” Journal of Clinical Microbiology, vol. 12, no. 5, pp. 641–643, 1980.

[25] K. Saito, T. Higuchi, A. Kurata, T. Fukuyasu, and K. Ashida, “Characterization of non-pigmented Staphylococcus chromogenes,” Journal of Veterinary Medical Science, vol. 58, no. 7, pp. 711–713, 1996.

[26] M. Kuroda, T. Ohta, I. Uchiyama, et al., “Whole genome sequencing of meticillin-resistant Staphylococcus aureus,” The Lancet, vol. 357, no. 9264, pp. 1225–1240, 2001.

[27] B. Steiner and D. Cruce, "A zymographic assay for detection of hyaluronidase activity on polyacrylamide gels and its application to enzymatic activity found in bacteria," Analytical Biochemistry, vol. 200, no. 2, pp. 405–410, 1992.

[28] L. Herron-Olson, J. R. Fitzgerald, J. M. Musser, and V. Kapur, “Molecular correlates of host specialization in Staphylococcus aureus,” PLoS ONE, vol. 2, no. 10, article e1120, 2007.

[29] M. T. G. Holden, E. J. Feil, J. A. Lindsay, et al., “Complete genomes of two clinical Staphylococcus aureus strains: evidence for the evolution of virulence and drug resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 26, pp. 9786–9791, 2004.

[30] L. M. Blank, P. Hugenholtz, and L. K. Nielsen, “Evolution of the hyaluronic acid synthesis (has) operon in Streptococcus zooepidemicus and other pathogenic streptococci,” Journal of Molecular Evolution, vol. 67, no. 1, pp. 13–22, 2008.

[31] D. J. Harrington, I. C. Sutcliffe, and N. Chanter, “The molecular basis of Streptococcus equi infection and disease,” Microbes and Infection, vol. 4, no. 4, pp. 501–510, 2002.

[32] L. A. Devriese and P. Oeding, “Coagulase and heat resistant nuclease producing Staphylococcus epidermidis strains from animals,” Journal of Applied Bacteriology, vol. 39, no. 2, pp. 197–207, 1975.